Vivos Therapeutics (VVOS) — Amman Bradford K. Receives Award

What Happened

• Amman Bradford K., Principal Accounting Officer of Vivos Therapeutics (VVOS), received equity compensation on July 31, 2026. The filing reports (1) a grant/award of 250,000 shares at $0.41 per share (value $102,500) and (2) a grant of 150,000 stock options priced at $0.41 per share (reported value $61,500). These are awards (not open‑market purchases or sales).

Key Details

• Transaction date: July 31, 2026. Reported on Form 4 filed August 26, 2026 (appears to be filed late; Form 4s are typically due within two business days).
• Awards: 250,000 shares @ $0.41 = $102,500; 150,000 options @ $0.41 = $61,500. Combined reported value: $164,000.
• Derivative note: the 150,000-item is a stock option grant (derivative instrument).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The option grant (150,000) was made under the issuer’s 2024 Omnibus Equity Incentive Plan. Per the footnote, the options “shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026” (as stated in the filing).

Context

• The 150,000 instruments are options (a derivative grant); they are not exercised or sold in this filing. Vesting terms determine when the insider can exercise them for shares.
• Stock awards and option grants are common forms of executive compensation and do not reflect an open‑market purchase or sale of company stock.
• The filing date (Aug 26, 2026) is substantially after the July 31, 2026 grant date, which may indicate a late disclosure.